The global Gene Panel Market is poised for exceptional growth as healthcare providers increasingly integrate genomic testing into routine clinical practice to support personalized treatment decisions and earlier disease identification. “According to a recent study by SNS Insider, the global Gene Panel Market size valued at USD 3.68 billion in 2025, is anticipated to grow to USD 17.18 billion by 2035, registering a CAGR of 16.69% over the 2026–2035 forecast period.”
The healthcare sector is currently experiencing a revolution in the form of a growing importance of genomic data in the process of diagnosing diseases, choosing treatment approaches, and managing patients. The development of sequencing techniques, increased lab capabilities, and knowledge about personalized care have prompted wider use of gene panel tests in hospitals, clinical laboratories, pharmaceutical firms, and research institutions.
In the context of the ongoing revolution in precision medicine, gene panel testing is becoming an indispensable component of diagnostics and personalized care in many treatment areas.
Precision Genomics Continues to Reshape Clinical Decision-Making
Today, healthcare practitioners are using more genomics to gain more accurate understanding of diseases, identify clinically important genetic mutations, and make decisions about targeted treatment options. In addition, current sequencing technology provides more efficient analysis with less time required for laboratory procedures.
The use of new technological approaches, such as bioinformatics systems, artificial intelligence, and genomic analytics is contributing to the process of interpreting complicated genetic data. The application of such technologies helps get more clinical information from genetic data.
There is also increased partnership between biotech firms, research organizations, and health care facilities in the efforts to enhance availability of genomic testing services and boost innovations within the precision medicine sector.
Key Market Findings Highlight High-Growth Opportunities
Among application areas, oncology was responsible for 47.56% of revenues in the global market share in 2025 due to the high significance of genomic profiling in diagnosing, selecting treatments and monitoring cancers.
Pharmacogenomics, on the other hand, will be characterized by the highest CAGR of 19.28% until 2035 as healthcare providers use genetics in order to select medicines that are the most effective for patients.
Looking from the product side, test kits accounted for 58.34% of total revenues in 2025 because of standardized processes and extensive usage in various laboratories. Testing services will demonstrate the highest CAGR of 17.92% because of rising outsourcing of genomic testing to specialist laboratories.
The adoption of technologies is changing fast. Hybridization-based sequencing held 54.21% of total revenue in 2025 being the best choice for thorough genomic analyses. Nevertheless, amplicon-based sequencing will be growing the fastest at a CAGR of 18.45% until 2035 thanks to rising need in targeted testing, shorter processes and cost-effective solutions.
In the case of end-users, the share of hospitals and laboratories was seen to be 52.89%, whereas in terms of growth rates, pharma and biotechnology companies are expected to grow at a CAGR of 18.67%. This is due to investments made in biomarkers and drugs.
Innovation Across Genomic Technologies Strengthens Market Outlook
The constant advancements made in sequencing technology, automation systems, and digital processing are making gene panel testing clinically more useful than ever before. Healthcare providers are becoming more committed to building genomic testing facilities that would make possible fast, large-scale, and high-quality testing in both diagnostic and research purposes.
The increasing interest in genomic approaches that do not involve invasive procedures, as well as in companion diagnostics and personalized treatment strategies, will probably make gene panel testing even more widespread in the future.
Regional Markets Continue to Present Strong Growth Potential
The North American region dominated the global market share with 41.62% in 2025. This domination was due to the well-developed healthcare system in this region, along with the implementation of genomics medicine in the region, biotechnological developments, and clinical research capabilities.
On the other hand, the Asia-Pacific region is expected to be the fastest-growing regional market in the next few years at a CAGR of 18.78%. Growing investment in healthcare, genomics research, improved laboratory facilities, and increasing popularity of personalized medicine offer numerous growth opportunities for the Asia-Pacific region.
Industry Leaders Continue to Advance Genomic Innovation
The competitive landscape of the gene panel market is expected to continue to be very dynamic due to the investment made by top genomics firms into sequencing platforms, automation in labs, bioinformatics solutions, and collaborations to promote clinical use of the tests.
Top firms that operate in the global gene panel market are Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, Roche Diagnostics, BGI Genomics, Eurofins Genomics, Myriad Genetics, Guardant Health, and SOPHiA GENETICS.
An SNS Insider analyst Parry Kardani commented, "The rapid convergence of next-generation sequencing, precision medicine, and advanced bioinformatics is transforming genomic diagnostics worldwide. As healthcare systems increasingly embrace personalized care models, gene panel testing is expected to play a pivotal role in improving diagnostic accuracy and enabling more targeted therapeutic decisions."
About the Author
Get in touch
